AbbVie Inc.





Market Closed - Nyse 04:00:02 2023-12-08 pm EST Intraday chart for AbbVie Inc. 5-day change 1st Jan Change
149.28 USD +0.89% +4.09% -7.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup DJ
S&P 500 Rises for Sixth Straight Week as Focus Shifts to Fed Meeting, Inflation Data MT
News Highlights : Top Financial Services News of the Day DJ
News Highlights : Top Company News of the Day DJ
AbbVie to focus on smaller deals after buying spree RE
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Drop Thursday Afternoon MT
AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says MT
Sector Update: Health Care MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say RE
Bain scores over tenfold return with $8.7 billion Cerevel sale RE
Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook MT
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs MT
Trending : AbbVie to Buy Cerevel for $45 a Share DJ
Are rate cuts are coming early next year?
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout RE
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research MT
Transcript : AbbVie Inc., Cerevel Therapeutics Holdings, Inc. - M&A Call CI
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data DJ
AbbVie: acquisition of Cerevel Therapeutics CF
Cerevel options trading surge before AbbVie deal news raises eyebrows RE
AbbVie to buy drug developer Cerevel for $8.7 billion RE
Health Flat as Obesity-Drug Stock Craze Eases -- Health Care Roundup DJ
AbbVie Signs $8.7 Billion Deal to Acquire Cerevel Therapeutics MT
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-7.63% 264 B $
+63.47% 538 B $
+42.56% 430 B $
-12.58% 372 B $
-6.49% 263 B $
-12.81% 232 B $
+1.35% 198 B $
-9.77% 197 B $
-43.83% 163 B $
+2.47% 144 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse
  4. News AbbVie Inc.
  5. Alvotech Says US FDA Accepted Refiled Biologics License Application for Humira Biosimilar
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments